Shots:Mission Therapeutics has reported the divestment of its P-II-ready asset MTX652, to Dimerix for initial development in Acute Kidney Injury (AKI)As per the deal, Mission will receive ~$292M in upfront, development & commercial milestones, plus up to double-digit tiered royalties on global net salesThe divestment aligns with Mission’s strategy to maximize its…
Shots:Thermo Fisher Scientific has agreed to sell its microbiology business to Astorg for ~$1.075B, incl. cash & a $50M seller note, as part of its portfolio optimization strategyThe divested unit, which offers antimicrobial susceptibility testing and culture media solutions, generated $645M in revenue in 2025 and operates within Thermo Fisher’s Specialty Diagnostics segment…
Shots:CareDx has entered a definitive agreement to divest its Lab Products business, incl. PCR & NGS-based transplant diagnostics, to EuroBio Scientific for $170M in cash Divestiture aims to streamline operations and refocus on core Precision Medicine Testing Services and digital solutions, while retaining exclusive North America rights to distribute post-transplant monitoring IVD tests, incl. AlloSeq…
Shots:Garda Therapeutics has entered into a definitive agreement to acquire Assertio, delisting it from NasdaqAs per the deal, Garda will acquire Assertio for $18/share in cash (~$125.1M) plus a non-tradeable CVR related to potential future milestones for Sprix, with the deal expected to close in Q2’26 & remaining shares acquired later via a…
Shots:Lonza has agreed to divest its Capsules & Health Ingredients (CHI) business to Lone Star Funds for an enterprise value of CHF 2.3B (~$3B), receiving CHF 1.7B (~$2.2B) upfront while retaining a 40% stake with preferential participation in future exit proceedsLonza is expecting total undiscounted proceeds of ≥CHF 3B (~$4B) from CHI via…
Shots:Novartis AG has signed an agreement with ChrysCapital to divest its 70.68% stake in Novartis India Limited (NIL), following a strategic review initiated in Feb 2024The transaction, subject to customary closing conditions, is expected to close in Q3’26; the Board of NIL was formally notified post-signingPost-divestment, Novartis will further its transition into…
